Raised Cerebrospinal Fluid BAFF and APRIL Levels in Anti-N-methyl-d-aspartate Receptor Encephalitis: Correlation with Clinical Outcome.

Bo Deng,Xiao-Ni Liu,Xiang Li,Xiang Zhang,Chao Quan,Xiang-Jun Chen
DOI: https://doi.org/10.1016/j.jneuroim.2017.01.012
IF: 3.221
2017-01-01
Journal of Neuroimmunology
Abstract:In this study, we aimed to assess the levels of B cell activating factor from the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in cerebrospinal fluid (CSF) of patients with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis and determine their correlation with clinical outcome. BAFF and APRIL concentrations in CSF and serum from 40 patients with anti-NMDAR encephalitis and 20 controls were measured by enzyme-linked immunosorbent assay (ELISA). Compared with controls, the levels of both BAFF and APRIL in CSF were significantly increased in patients with anti-NMDAR encephalitis (p<0.001 and p<0.001). Patients with unfavorable outcome had higher levels of BAFF and APRIL in CSF than those who had favorable outcome (p<0.05 and p<0.05). BAFF and APRIL levels in CSF were elevated and associated with clinical outcome in patients with anti-NMDAR encephalitis, indicating that they may be valuable biomarkers to this disease.
What problem does this paper attempt to address?